Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 21;64(6):e02566-19.
doi: 10.1128/AAC.02566-19. Print 2020 May 21.

Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

Robert K Flamm  1 , Leonard R Duncan  2 , Kamal A Hamed  3 , Jennifer I Smart  3 , Rodrigo E Mendes  1 , Michael A Pfaller  1   4
Affiliations

Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

Robert K Flamm et al. Antimicrob Agents Chemother. .

Abstract

Ceftobiprole medocaril is an advanced-generation cephalosporin prodrug that has qualified infectious disease product status granted by the US FDA and is currently being evaluated in phase 3 clinical trials in patients with acute bacterial skin and skin structure infections (ABSSSIs) and in patients with Staphylococcus aureus bacteremia. In this study, the activity of ceftobiprole and comparators was evaluated against more than 7,300 clinical isolates collected in the United States from 2016 through 2018 from patients with skin and skin structure infections. The major species/pathogen groups were S. aureus (53%), Enterobacterales (23%), Pseudomonas aeruginosa (7%), beta-hemolytic streptococci (6%), Enterococcus spp. (4%), and coagulase-negative staphylococci (2%). Ceftobiprole was highly active against S. aureus (MIC50/90, 0.5/1 mg/liter; 99.7% susceptible by EUCAST criteria; 42% methicillin-resistant S. aureus [MRSA]). Ceftobiprole also exhibited potent activity against other Gram-positive cocci. The overall susceptibility of Enterobacterales to ceftobiprole was 84.8% (>99.0% susceptible for isolate subsets that exhibited a non-extended-spectrum β-lactamase [ESBL] phenotype). A total of 74.4% of P. aeruginosa, 100% of beta-hemolytic streptococci and coagulase-negative staphylococci, and 99.6% of Enterococcus faecalis isolates were inhibited by ceftobiprole at ≤4 mg/liter. As expected, ceftobiprole was largely inactive against Enterobacterales that contained ESBL genes and Enterococcus faecium Overall, ceftobiprole was highly active against most clinical isolates from the major Gram-positive and Gram-negative skin and skin structure pathogen groups collected at U.S. medical centers participating in the SENTRY Antimicrobial Surveillance Program during 2016 to 2018. The broad-spectrum activity of ceftobiprole, including potent activity against MRSA, supports its further evaluation for a potential ABSSSI indication.

Keywords: ABSSSI; MRSA; SSTI; ceftobiprole; cephalosporin; skin; surveillance.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Species, groups, and numbers of U.S. isolates from skin and skin structure infections (2016 to 2018).
See this image and copyright information in PMC

References

    1. Pallin DJ, Espinola JA, Leung DY, Hooper DC, Camargo CA Jr., 2009. Epidemiology of dermatitis and skin infections in United States physicians’ offices, 1993–2005. Clin Infect Dis 49:901–907. doi: 10.1086/605434. - DOI - PubMed
    1. Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr., 2008. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 51:291–298. doi: 10.1016/j.annemergmed.2007.12.004. - DOI - PubMed
    1. Dryden MS. 2010. Complicated skin and soft tissue infection. J Antimicrob Chemother 65 Suppl 3:iii35–iii44. doi: 10.1093/jac/dkq302. - DOI - PubMed
    1. Lipsky BA, Moran GJ, Napolitano LM, Vo L, Nicholson S, Kim M. 2012. A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes. BMC Infect Dis 12:227. doi: 10.1186/1471-2334-12-227. - DOI - PMC - PubMed
    1. Leong HN, Kurup A, Tan MY, Kwa ALH, Liau KH, Wilcox MH. 2018. Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infect Drug Resist 11:1959–1974. doi: 10.2147/IDR.S172366. - DOI - PMC - PubMed

Publication types

LinkOut - more resources